These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 25954050)

  • 1. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion.
    Wang Y; Gusarova V; Banfi S; Gromada J; Cohen JC; Hobbs HH
    J Lipid Res; 2015 Jul; 56(7):1296-307. PubMed ID: 25954050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys.
    Gusarova V; Alexa CA; Wang Y; Rafique A; Kim JH; Buckler D; Mintah IJ; Shihanian LM; Cohen JC; Hobbs HH; Xin Y; Valenzuela DM; Murphy AJ; Yancopoulos GD; Gromada J
    J Lipid Res; 2015 Jul; 56(7):1308-17. PubMed ID: 25964512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
    Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
    Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice.
    Ando Y; Shimizugawa T; Takeshita S; Ono M; Shimamura M; Koishi R; Furukawa H
    J Lipid Res; 2003 Jun; 44(6):1216-23. PubMed ID: 12671033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase.
    Shimizugawa T; Ono M; Shimamura M; Yoshida K; Ando Y; Koishi R; Ueda K; Inaba T; Minekura H; Kohama T; Furukawa H
    J Biol Chem; 2002 Sep; 277(37):33742-8. PubMed ID: 12097324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance.
    Adam RC; Mintah IJ; Alexa-Braun CA; Shihanian LM; Lee JS; Banerjee P; Hamon SC; Kim HI; Cohen JC; Hobbs HH; Van Hout C; Gromada J; Murphy AJ; Yancopoulos GD; Sleeman MW; Gusarova V
    J Lipid Res; 2020 Sep; 61(9):1271-1286. PubMed ID: 32646941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids.
    Robciuc MR; Maranghi M; Lahikainen A; Rader D; Bensadoun A; Öörni K; Metso J; Minicocci I; Ciociola E; Ceci F; Montali A; Arca M; Ehnholm C; Jauhiainen M
    Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1706-13. PubMed ID: 23661675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein lipase- and hepatic triglyceride lipase- promoted very low density lipoprotein degradation proceeds via an apolipoprotein E-dependent mechanism.
    Medh JD; Fry GL; Bowen SL; Ruben S; Wong H; Chappell DA
    J Lipid Res; 2000 Nov; 41(11):1858-71. PubMed ID: 11060356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ANGPTL3 deficiency impairs lipoprotein production and produces adaptive changes in hepatic lipid metabolism.
    Burks KH; Xie Y; Gildea M; Jung IH; Mukherjee S; Lee P; Pudupakkam U; Wagoner R; Patel V; Santana K; Alisio A; Goldberg IJ; Finck BN; Fisher EA; Davidson NO; Stitziel NO
    J Lipid Res; 2024 Feb; 65(2):100500. PubMed ID: 38219820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
    Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
    Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL).
    Lee EC; Desai U; Gololobov G; Hong S; Feng X; Yu XC; Gay J; Wilganowski N; Gao C; Du LL; Chen J; Hu Y; Zhao S; Kirkpatrick L; Schneider M; Zambrowicz BP; Landes G; Powell DR; Sonnenburg WK
    J Biol Chem; 2009 May; 284(20):13735-13745. PubMed ID: 19318355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
    Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
    Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver.
    Mensenkamp AR; Jong MC; van Goor H; van Luyn MJ; Bloks V; Havinga R; Voshol PJ; Hofker MH; van Dijk KW; Havekes LM; Kuipers F
    J Biol Chem; 1999 Dec; 274(50):35711-8. PubMed ID: 10585451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma angiopoietin-like protein 3 (ANGPTL3) concentration is associated with uremic dyslipidemia.
    Shoji T; Hatsuda S; Tsuchikura S; Kimoto E; Kakiya R; Tahara H; Koyama H; Emoto M; Tabata T; Nishizawa Y
    Atherosclerosis; 2009 Dec; 207(2):579-84. PubMed ID: 19540497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3.
    Pisciotta L; Favari E; Magnolo L; Simonelli S; Adorni MP; Sallo R; Fancello T; Zavaroni I; Ardigò D; Bernini F; Calabresi L; Franceschini G; Tarugi P; Calandra S; Bertolini S
    Circ Cardiovasc Genet; 2012 Feb; 5(1):42-50. PubMed ID: 22062970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins.
    Fazio S; Minnier J; Shapiro MD; Tsimikas S; Tarugi P; Averna MR; Arca M; Tavori H
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3340-3348. PubMed ID: 28633452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of lipoprotein lipase induced cholesterol ester accumulation in human hepatoma HepG2 cells.
    Cianflone K; Avramoglu RK; Sawyez C; Huff MW
    Atherosclerosis; 1996 Feb; 120(1-2):101-14. PubMed ID: 8645351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of triglyceride metabolism by Angiopoietin-like proteins.
    Mattijssen F; Kersten S
    Biochim Biophys Acta; 2012 May; 1821(5):782-9. PubMed ID: 22063269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.
    Chen PY; Gao WY; Liou JW; Lin CY; Wu MJ; Yen JH
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence that cholesteryl ester and triglyceride accumulation in J774 macrophages induced by very low density lipoprotein subfractions occurs by different mechanisms.
    Evans AJ; Sawyez CG; Wolfe BM; Connelly PW; Maguire GF; Huff MW
    J Lipid Res; 1993 May; 34(5):703-17. PubMed ID: 8509711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.